Hyperthermia with Chemotherapy for Unresectable Gastric Cancer in a Patient with a Vagus Nerve Stimulator Implant: A Case Report

Overview

Journal Am J Case Rep

Specialty General Medicine

Date 2021 Aug 17

PMID 34400601

Authors

Hirozumi Sawai

Shuhei Ueno

Yoshimi Yamaguchi

Yuka Suzuki

Akemi Murata

Enami Suganuma

Kazuya Yamamoto

Hiromasa Kuzuya

Shuji Koide

Masaaki Kurimoto

Takeshi Yanagi

Hajime Koide

Atsushi Kamiya

Affiliations

Soon will be listed here.

Abstract

BACKGROUND Radiofrequency (RF) hyperthermia is commonly used as an adjunct to established treatment modalities such as chemotherapy and radiotherapy for the management of cancer patients. This case report aims to introduce the use of hyperthermia, in combination with chemotherapy, for the treatment of unresectable gastric cancer in a patient implanted with a vagus nerve stimulator (VNS). CASE REPORT A 55-year-old man with dermatomyositis, laryngeal squamous cell carcinoma in situ and double synchronous gastric cancer was found to have unresectable gastric disease during surgery despite neoadjuvant chemotherapy. Postoperatively, he received chemotherapy with RF hyperthermia. The patient had a VNS implant to treat epileptic seizures. VNS failure due to RF hyperthermia was an area of significant concern, and the procedures were completed with a full preparation to manage epileptic seizures in the event of its anticipated occurrence. Twenty-one thermotherapies were performed over 21 weeks. After 3 courses of S-1 chemotherapy (12 weeks) with RF hyperthermia without any adverse events, the regimen was changed to S-1+ CDDP combination chemotherapy (SP) and RF hyperthermia. The patient continued to receive treatment with a decrease in the size of the primary gastric tumors as well as lymph node metastases, without major adverse events, until he died due to disseminated disease. CONCLUSIONS We report the first case of unresectable gastric cancer with VNS implants in which chemo-hyperthermal therapy was safe and successful. This case report highlights the importance of providing a multidisciplinary treatment with appropriate measures for patients with intractable cancer who have received special treatments for underlying comorbidities.

References

Shoji H, Motegi M, Osawa K, Okonogi N, Okazaki A, Andou Y . A novel strategy of radiofrequency hyperthermia (neothermia) in combination with preoperative chemoradiotherapy for the treatment of advanced rectal cancer: a pilot study. Cancer Med. 2015; 4(6):834-43. PMC: 4472206. DOI: 10.1002/cam4.431. View

Lv F, Yu Y, Zhang B, Liang D, Li Z, You W . Inhibitory effects of mild hyperthermia plus docetaxel therapy on ER(+/-) breast cancer cells and action mechanisms. J Huazhong Univ Sci Technolog Med Sci. 2013; 33(6):870-876. DOI: 10.1007/s11596-013-1214-8. View

Nakajima T, Yamaguchi K, Boku N, Hyodo I, Mizusawa J, Hara H . Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). Gastric Cancer. 2020; 23(4):677-688. DOI: 10.1007/s10120-020-01043-x. View

Koizumi W, Kim Y, Fujii M, Kim H, Imamura H, Lee K . Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2013; 140(2):319-28. PMC: 3895196. DOI: 10.1007/s00432-013-1563-5. View

Hurwitz M . Hyperthermia and immunotherapy: clinical opportunities. Int J Hyperthermia. 2019; 36(sup1):4-9. DOI: 10.1080/02656736.2019.1653499. View

Hsu A, Mendelson L, Almhanna K . Immune Checkpoint Inhibitors in the Treatment of Gastrointestinal Malignancies: A Review of Current and Future Therapies. R I Med J (2013). 2020; 103(3):33-37. View

Multhoff G, Habl G, Combs S . Rationale of hyperthermia for radio(chemo)therapy and immune responses in patients with bladder cancer: Biological concepts, clinical data, interdisciplinary treatment decisions and biological tumour imaging. Int J Hyperthermia. 2016; 32(4):455-63. DOI: 10.3109/02656736.2016.1152632. View

Ryu J, Lee K, Joe C, Joo J, Lee N, Yoo H . Patient With Unresectable Cholangiocarcinoma Treated With Radiofrequency Hyperthermia in Combination With Chemotherapy: A Case Report. Integr Cancer Ther. 2017; 17(2):558-561. PMC: 6041912. DOI: 10.1177/1534735417722225. View

RANDALL W, Ardell J, Becker D . Differential responses accompanying sequential stimulation and ablation of vagal branches to dog heart. Am J Physiol. 1985; 249(1 Pt 2):H133-40. DOI: 10.1152/ajpheart.1985.249.1.H133. View

10.

Frey B, Weiss E, Rubner Y, Wunderlich R, Ott O, Sauer R . Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia. 2012; 28(6):528-42. DOI: 10.3109/02656736.2012.677933. View

11.

Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H . Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002; 3(8):487-97. DOI: 10.1016/s1470-2045(02)00818-5. View

12.

Jin H, Li P, Mao C, Zhu K, Chen H, Gao Y . Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability. Onco Targets Ther. 2020; 13:1751-1756. PMC: 7050039. DOI: 10.2147/OTT.S243298. View

13.

Hegyi G, Szigeti G, Szasz A . Hyperthermia versus Oncothermia: Cellular Effects in Complementary Cancer Therapy. Evid Based Complement Alternat Med. 2013; 2013:672873. PMC: 3638606. DOI: 10.1155/2013/672873. View

14.

Song M, Latorre G, Ivanovic-Zuvic D, Camargo M, Rabkin C . Autoimmune Diseases and Gastric Cancer Risk: A Systematic Review and Meta-Analysis. Cancer Res Treat. 2019; 51(3):841-850. PMC: 6639229. DOI: 10.4143/crt.2019.151. View

15.

Skonieczki B, Wells C, Wasser E, Dupuy D . Radiofrequency and microwave tumor ablation in patients with implanted cardiac devices: is it safe?. Eur J Radiol. 2010; 79(3):343-6. DOI: 10.1016/j.ejrad.2010.04.004. View

16.

Garg A, Galluzzi L, Apetoh L, Baert T, Birge R, Bravo-San Pedro J . Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol. 2015; 6:588. PMC: 4653610. DOI: 10.3389/fimmu.2015.00588. View

17.

Landgren A, Landgren O, Gridley G, Dores G, Linet M, Morton L . Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer. 2011; 117(6):1163-71. PMC: 3052786. DOI: 10.1002/cncr.25524. View

18.

Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N . Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019; 4(7):501-510. DOI: 10.1016/S2468-1253(19)30083-4. View

19.

Sidoff L, Dupuy D . Clinical experiences with microwave thermal ablation of lung malignancies. Int J Hyperthermia. 2016; 33(1):25-33. DOI: 10.1080/02656736.2016.1204630. View

20.

Hurwitz M, Stauffer P . Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. Semin Oncol. 2014; 41(6):714-29. DOI: 10.1053/j.seminoncol.2014.09.014. View